Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pamvatamig (MCLA-129)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Betta Pharma, Merus

Drug class:

EGFR inhibitor, c-MET inhibitor

Related drugs:

‹

EMD 1204831 (0)

PF-04217903 (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

savolitinib (29)

capmatinib (23)

unecritinib (6)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	MCLA-129 Sensitive: C2 – Inclusion Criteria MCLA-129 Sensitive : C2	MCLA-129 Sensitive: C2 – Inclusion Criteria MCLA-129 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MCLA-129 Sensitive: C3 – Early Trials osimertinib + MCLA-129 Sensitive : C3	osimertinib + MCLA-129 Sensitive: C3 – Early Trials osimertinib + MCLA-129 Sensitive : C3
EGFR E746_A750del	Non Small Cell Lung Cancer	EGFR E746_A750del	Non Small Cell Lung Cancer	MCLA-129 Sensitive: D – Preclinical MCLA-129 Sensitive : D	MCLA-129 Sensitive: D – Preclinical MCLA-129 Sensitive : D